Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Not Available].

A Matsumori1

  • 1Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Third Division, Department of Internal Medicine, Kyoto University Hospital, Kyoto, Japan.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lessons learned from experimental myocarditis.

Herz·2012
Same author

Increased serum N-terminal pro-B-type natriuretic peptide and left ventricle diastolic dysfunction in patients with hepatitis C virus infection.

Journal of viral hepatitis·2012
Same author

HLA-DPbeta chain may confer the susceptibility to hepatitis C virus-associated hypertrophic cardiomyopathy.

International journal of immunogenetics·2008
Same author

Role of hepatitis C virus in cardiomyopathies.

Ernst Schering Research Foundation workshop·2005
Same author

The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy.

Tissue antigens·2005
Same author

Measurements of cardiac troponin T in patients with hypertrophic cardiomyopathy.

Heart (British Cardiac Society)·2003
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Vesnarinone improved survival and reduced heart damage in a murine heart failure model by inhibiting cytokine production, including tumor necrosis factor-alpha. This suggests reducing cytokine release may be key to vesnarinone

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Cytokines are increasingly recognized as key factors in heart failure pathogenesis and pathophysiology.
  • Elevated circulating cytokine levels are observed in heart failure patients.
  • Certain cytokines can negatively impact myocardial contractility both in vitro and in vivo.

Purpose of the Study:

  • To investigate the effects of vesnarinone on cytokine production in a murine model of congestive heart failure.
  • To determine if vesnarinone's beneficial effects on heart failure are related to its impact on cytokine regulation.

Main Methods:

  • Utilized a murine model of congestive heart failure induced by encephalomyocarditis virus infection.
  • Administered vesnarinone treatment to assess its impact on survival and myocardial damage.

Related Experiment Videos

  • Measured natural killer cell activity and the production of tumor necrosis factor-alpha (TNFalpha).
  • Assessed cytokine production by peripheral blood and endothelial cells following vesnarinone treatment.

    • Main Results:

    • Vesnarinone treatment significantly improved survival and reduced myocardial damage in the heart failure model.
    • Vesnarinone inhibited the increase in natural killer cell activity and TNFalpha production.
    • The drug also suppressed the production of various cytokines by peripheral blood and endothelial cells.

    Conclusions:

    • Vesnarinone plays a significant role in regulating cytokine production.
    • Reduction in cytokine release may contribute to the therapeutic benefits of vesnarinone in heart failure treatment.
    • Further research into cytokine-modulating inotropic agents could lead to better heart failure therapies.